Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Good morning. The M&A streak continues. Read on for the news today.
Novo to buy MASH drugmaker Akero Therapeutics
Novo Nordisk said this morning that it will buy Akero Therapeutics, the developer of a drug to treat the liver disease known as MASH, for up to $5.2 billion.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in